| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 7, 2008
Accepted on March 8, 2009
From the Division of Gene Therapy Science (H.H., H.N., Y.T., H.K., M.M., K.T., Y.K.), the Department of Geriatric Medicine (Y.T., H.K.), and the Division of Clinical Gene Therapy and Graduate School of Medicine (K.N., R.M.), Osaka University, Japan; and the Department of Cell Biology and Molecular Medicine (J.S.), UMDNJ-New Jersey Medical School, Newark.
* To whom correspondence should be addressed. E-mail: nakagami{at}gts.med.osaka-u.ac.jp.
Objective—In the functional screening of a human heart cDNA library to identify a novel antiangiogenic factor, the prime candidate gene was "four-and-a-half LIM only protein-2" (FHL-2). The goal of this study is to clear the mechanism of antiangiogenic signaling of FHL-2 in endothelial cells (ECs).
Methods and Results—Overexpressed FHL-2 strongly inhibited vascular endothelial growth factor (VEGF)-induced EC migration. In the angiogenic signaling, we focused on sphingosine kinase-1 (SK1), which produces sphingosine-1-phosphate (S1P), a bioactive sphingolipid, as a potent angiogenic mediator in ECs. Immunoprecipitation and immunostaining analysis showed that FHL-2 might bind to SK1. Importantly, overexpression of FHL-2 in ECs inhibited VEGF-induced SK1 activity, phosphatidylinositol 3-kinase activity, and phosphorylation of Akt and eNOS. In contrast, overexpression of FHL-2 had no effect on S1P-induced Akt phosphorylation. Interestingly, VEGF stimulation decreased the binding of FHL-2 and SK1. Depletion of FHL-2 by siRNA increased EC migration accompanied with SK1 and Akt activation, and increased the expression of VEGF receptor-2 which further enhanced VEGF signaling. Furthermore, injection of FHL-2 mRNA into Xenopus embryos resulted in inhibition of vascular network development, assessed by in situ hybridization with endothelial markers.
Conclusions—FHL-2 may regulate phosphatidylinositol 3-kinase/Akt via direct suppression of the SK1-S1P pathway in ECs.
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |